Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

enGene Therapeutics Inc. (ENGN) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

enGene Therapeutics Inc. (ENGN), most recent 12 months reported: net loss $130.36M, free cash flow -$104M. Latest balance sheet on file: liquid cash $266.32M, total debt $25.35M, net cash $240.97M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): MOSAIC IMMUNOENGINEERING, INC. · CEL-SCI CORPORATION · Denali Therapeutics Inc. · ELOXX PHARMACEUTICALS, INC. · ENTERA BIO LTD. · ESTRELLA IMMUNOPHARMA, INC. · EXOZYMES INC. · GREEN PLANET BIOENGINEERING CO., LTD.

Stock screener

Watchlist